Hui–Hsuan Kuo

657 total citations
8 papers, 418 citations indexed

About

Hui–Hsuan Kuo is a scholar working on Oncology, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Hui–Hsuan Kuo has authored 8 papers receiving a total of 418 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Molecular Biology and 2 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Hui–Hsuan Kuo's work include Chemotherapy-induced cardiotoxicity and mitigation (2 papers), 3D Printing in Biomedical Research (2 papers) and vaccines and immunoinformatics approaches (1 paper). Hui–Hsuan Kuo is often cited by papers focused on Chemotherapy-induced cardiotoxicity and mitigation (2 papers), 3D Printing in Biomedical Research (2 papers) and vaccines and immunoinformatics approaches (1 paper). Hui–Hsuan Kuo collaborates with scholars based in United States, Canada and Israel. Hui–Hsuan Kuo's co-authors include Paul W. Burridge, Tarek Magdy, Hananeh Fonoudi, Mariam Jouni, Marisol Romero‐Tejeda, K. Ashley Fetterman, Ondine Cleaver, Zoltán Jakus, Xiaolei Liu and Edward B. Thorp and has published in prestigious journals such as Nature, Circulation and Cell stem cell.

In The Last Decade

Hui–Hsuan Kuo

8 papers receiving 414 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hui–Hsuan Kuo United States 7 190 153 102 71 64 8 418
Francisco X. Galdos United States 8 181 1.0× 73 0.5× 90 0.9× 69 1.0× 40 0.6× 13 330
Germaine D. Agollah United States 11 232 1.2× 93 0.6× 58 0.6× 84 1.2× 104 1.6× 22 630
Paul Mondragón‐Terán Mexico 10 161 0.8× 51 0.3× 45 0.4× 59 0.8× 42 0.7× 47 323
Lilach Koren Israel 12 174 0.9× 50 0.3× 51 0.5× 27 0.4× 88 1.4× 22 408
Pratiek N. Matkar Canada 15 332 1.7× 45 0.3× 55 0.5× 46 0.6× 90 1.4× 24 558
Omozuanvbo Aisiku United States 8 174 0.9× 46 0.3× 53 0.5× 42 0.6× 207 3.2× 10 543
Jung-Joon Min South Korea 13 167 0.9× 72 0.5× 21 0.2× 46 0.6× 159 2.5× 20 522
Marina Barreto Felisbino Brazil 10 286 1.5× 64 0.4× 90 0.9× 58 0.8× 10 0.2× 14 414
Martina Dreßen Germany 14 521 2.7× 38 0.2× 184 1.8× 133 1.9× 72 1.1× 34 720
Jerry Xiao United States 9 149 0.8× 67 0.4× 18 0.2× 63 0.9× 72 1.1× 22 310

Countries citing papers authored by Hui–Hsuan Kuo

Since Specialization
Citations

This map shows the geographic impact of Hui–Hsuan Kuo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hui–Hsuan Kuo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hui–Hsuan Kuo more than expected).

Fields of papers citing papers by Hui–Hsuan Kuo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hui–Hsuan Kuo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hui–Hsuan Kuo. The network helps show where Hui–Hsuan Kuo may publish in the future.

Co-authorship network of co-authors of Hui–Hsuan Kuo

This figure shows the co-authorship network connecting the top 25 collaborators of Hui–Hsuan Kuo. A scholar is included among the top collaborators of Hui–Hsuan Kuo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hui–Hsuan Kuo. Hui–Hsuan Kuo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Hu, Yingying, Hsin‐Che Huang, Hui–Hsuan Kuo, et al.. (2024). Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens. Journal of Biomedical Science. 31(1). 94–94. 5 indexed citations
2.
Linares, Juan F., Ángeles Durán, Anxo Martínez-Ordóñez, et al.. (2022). The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62. Cell Reports. 39(6). 110792–110792. 53 indexed citations
3.
Kuo, Hui–Hsuan, et al.. (2022). Next generation patient derived tumor organoids. Translational research. 250. 84–97. 11 indexed citations
4.
Magdy, Tarek, Mariam Jouni, Hui–Hsuan Kuo, et al.. (2021). Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity. Circulation. 145(4). 279–294. 59 indexed citations
5.
Magdy, Tarek, Zhengxin Jiang, Mariam Jouni, et al.. (2021). RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy. Cell stem cell. 28(12). 2076–2089.e7. 45 indexed citations
6.
Kuo, Hui–Hsuan, Xiaozhi Gao, K. Ashley Fetterman, et al.. (2020). Negligible-Cost and Weekend-Free Chemically Defined Human iPSC Culture. Stem Cell Reports. 14(2). 256–270. 89 indexed citations
7.
Magdy, Tarek, Hui–Hsuan Kuo, & Paul W. Burridge. (2020). Precise and Cost-Effective Nanopore Sequencing for Post-GWAS Fine-Mapping and Causal Variant Identification. iScience. 23(4). 100971–100971. 10 indexed citations
8.
Liu, Xiaolei, Xiaowu Gu, László Bálint, et al.. (2020). Lymphoangiocrine signals promote cardiac growth and repair. Nature. 588(7839). 705–711. 146 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026